Two imaging modalities predict progression from mild cognitive impairment to Lewy body dementia

Takeaway

  • People with mild cognitive impairment who have core clinical features of Lewy body dementia have imaging biomarker abnormalities that are linked to clinical phenotypes.

Why this matters

  • This novel study uses two imaging modalities to identify biomarkers that are sensitive to different pathologic processes in prodromal Lewy body dementia. The findings suggest that amyloid-β positron emission tomography and dopamine transporter imaging are complementary in characterizing clinical phenotypes of individuals at risk of progressing to Lewy body dementia.

  • The finding that amyloid-β positivity is linked to worse cognitive function highlights a potential therapeutic target for slowing the progression from prodromal to overt Lewy body dementia.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.